HGF/c‐Met Promotes Breast Cancer Tamoxifen Resistance Through the EZH2/HOTAIR‐miR‐141/200a Feedback Signaling Pathway
Molecular Carcinogenesis · 2025
DOI: 10.1002/mc.23878 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2025. Verfasst von Xiaofeng Lai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Enhancer of Zeste Homolog 2 Protein, Hepatocyte Growth Factor, Tamoxifen. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: This study was funded by the National Natural Science Foundation of China (No. 81972710, 82073202, 82372960, 81902712), the Fund for Scientific and Technologic….
Abstract (Originalsprache)
Tamoxifen is one of the most frequently used endocrine medications for the treatment of estrogen receptor‐positive (ER + ) breast cancer (BC). Unfortunately, tamoxifen resistance (TR) brings more challenges to the clinical treatment, and the mechanisms of TR have not yet been fully clarified. HGF/c‐Met is closely associated with cancer metastasis, but whether it is involved in TR remains unclear. In our study, we found that the activation of HGF/c‐Met was crucial for TR maintenance. Synergistic interaction with HOTAIR and EZH2 accelerated HGF expression by repressing miR‐141/200a. Additionally, HGF/c‐Met activated NF‐κB, forming a positive feedback loop of EZH2/HOTAIR‐miR‐141/200a‐HGF/c‐Met‐NF‐κB. Our findings indicated that HGF/c‐Met functioned as an important biomarker for TR, and HGF/c‐Met inhibition provided a novel approach to TR treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
- State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Biochemistry and Molecular Biology, The Fourth Military Medical University, Xi'an, China.
- Department of Clinical Laboratory Medicine, Fuzhou General Clinical Medical School (The 900TH Hospital), Fujian Medical University, Fuzhou, China.
- Fujian Key Laboratory of Aptamers Technology, Affiliated Dongfang Hospital of School of Medicine, Xiamen University, Fuzhou, China.
- Department of Oncology, Shaanxi Provincial People's Hospital, Xi'an, China.
- The Faculty of Hepatopancreatobiliary Surgery, The First Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China.
ORCID-Profile: Jian Zhang
Förderung
- This study was funded by the National Natural Science Foundation of China (No. 81972710, 82073202, 82372960, 81902712), the Fund for Scientific and Technologic…
Zitieren
APA
Lai, X., Zhang, Y., Li, M., Yu, S., Wang, S., Zhang, S., Niu, H., Chen, L., Lan, X., Zhang, J., & Chen, S. (2025). HGF/c‐Met Promotes Breast Cancer Tamoxifen Resistance Through the EZH2/HOTAIR‐miR‐141/200a Feedback Signaling Pathway. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23878
Vancouver
Lai X, Zhang Y, Li M, Yu S, Wang S, Zhang S, et al. HGF/c‐Met Promotes Breast Cancer Tamoxifen Resistance Through the EZH2/HOTAIR‐miR‐141/200a Feedback Signaling Pathway. Molecular Carcinogenesis. 2025. doi:10.1002/mc.23878
BibTeX
@article{Lai2025,
author = {Lai, Xiaofeng and Zhang, Yuan and Li, Mengyang and Yu, Shentong and Wang, Shuiliang and Zhang, Shenghang and Niu, Huimin and Chen, Li and Lan, Xiaopeng and Zhang, Jian and Chen, Suning},
title = {HGF/c‐Met Promotes Breast Cancer Tamoxifen Resistance Through the EZH2/HOTAIR‐miR‐141/200a Feedback Signaling Pathway},
journal = {Molecular Carcinogenesis},
year = {2025},
doi = {10.1002/mc.23878}
}
EUVIMED